ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
Securing broad patent coverage is part of IVT's strategy to maximize the market potential of its VacciMax® platform in the largest pharmaceutical markets in the world; including the US, Europe, Canada, Australia and Japan. The company's VacciMax® technology is based on a novel approach to the use of liposomes in an oil emulsion. IVT has discovered that liposomes, stabilized in the VacciMax® technology, significantly enhance antibody production, creating a more rapid immune response, following a single vaccination. The responses are also long lasting, without requiring booster immunizations.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.